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SUMMARY
Purpose: Several recent reports of genomic microdele-
tions in epilepsy will generate further research; discov-
ery of more microdeletions and other important classes
of variants may follow. Detection of such genetic abnor-
malities in patients being evaluated for surgical
treatment might raise concern that a genetic defect,
possibly widely expressed in the brain, will affect surgical
outcome.
Methods: A reevaluation was undertaken of clinical pre-
surgical data, histopathology of surgical specimen, and
postsurgical outcome in patients with mesial temporal
lobe epilepsy (MTLE) who have had surgical treatment for
their drug-resistant seizures, and who have been found to
have particular genomicmicrodeletions.
Key Findings: Three thousand eight hundred twelve
patients with epilepsy were genotyped and had a genome-
wide screen to identify copy number variation. Ten
patients with MTLE, who had resective epilepsy surgery,
were found to have 16p13.11microdeletions or othermic-
rodeletions >1 Mb. On histopathology, eight had classical
hippocampal sclerosis (HS), one had nonspecific findings,
and one had a hamartoma. Median postsurgical follow-up
time was 48 months (range 10–156 months). All patients
with HS were seizure-free after surgery, International
League Against Epilepsy (ILAE) outcome class 1, at last
follow-up; the patient with nonspecific pathology had
recurrence of infrequent seizures after 7 years of seizure
freedom. The patient with a hamartoma never became
seizure-free.
Significance: Large microdeletions can be found in
patients with ‘‘typical’’ MTLE. In this small series, patients
with MTLE who meet criteria for resective surgery and
harbor large microdeletions, at least those we have
detected, can have a good postsurgical outcome. Our
findings add to the spectrum of causal heterogeneity of
MTLE + HS.
KEY WORDS: Epilepsy surgery, Hippocampal sclerosis,
Temporal lobectomy, Deletions.
Recurrent genomic microdeletions have recently been
identified in ‘‘common’’ sporadic epilepsies, those not
obviously part of a genetic syndrome. 15q13.3, 15q11.2,
and 16p13.3 microdeletions together underlie 3% of idio-
pathic generalized epilepsies (IGEs) (Helbig et al., 2009;
de Kovel et al., 2010; Mefford et al., 2010). We identified
16p13.11 and other large microdeletions in 0.8% of
patients with epilepsy (Heinzen et al., 2010). As more mic-
rodeletions are reported and technologies for the detection
of these and other putatively causal variants become more
accessible, interest in searching for such variants will
increase.
A number of patients in our initial cohort had mesial
temporal lobe epilepsy (MTLE) and had resective epilepsy
surgery, and some were found to harbor particular mic-
rodeletions. The detection of a microdeletion might raise
concern about its potential influence on outcome measures
following epilepsy surgery, with regard to seizure control
or other domains. The presence of a microdeletion could
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represent widespread brain involvement, similar to cogni-
tive impairment or secondary generalized tonic–clonic sei-
zures, both of which reduce chances of good outcome
across various domains after epilepsy surgery (Malmgren
et al., 2008; Spencer & Huh, 2008). On the other hand,
such microdeletions might not affect outcome, for example
because of spatial variability in gene expression (Hardy
et al., 2009). We evaluated systematically the effect of
large microdeletions on outcome after surgery in patients
with MTLE.
Methods
This work was approved by the relevant local research
ethics committees. All patients provided written informed
consent.
Microdeletions were identified as described previously
(Heinzen et al., 2010). Only microdeletions >1 Mb, or
16p13.11 microdeletions, were considered (Heinzen et al.,
2010). We reevaluated clinical history and presurgical
investigations [magnetic resonance imaging (MRI) brain
scan, video–electroencephalography (EEG) telemetry, neu-
ropsychometry, neuropsychiatric assessment]. Histopathol-
ogy of the surgical specimen was reviewed. Postsurgical
outcome was evaluated in terms of seizure control at 1 year
and at last follow-up, using the International League
Against Epilepsy (ILAE) outcome classification (Wieser
et al., 2001), antiepileptic drug changes, psychiatric out-
come, neuropsychometry, and employment outcome.
Results
Three thousand eight hundred twelve patients with epi-
lepsy (>90% with partial epilepsies) were genotyped and
had a genome-wide screen to identify copy number varia-
tion. Ten patients with MTLE who had undergone therapeu-
tic resection had large microdeletions. Follow-up duration
after surgery ranged from 10–156 months. Three patients
had 16p13.11 microdeletion and two had 15q11.2 microde-
letion; the full range of microdeletions is listed in Table 1.
Demographic and clinical data are summarized in
(Table S1), including details of the type of surgery and out-
come of surgery across several domains, including seizure
control. The histopathologic results from analysis of the sur-
gical specimen are listed in Table 2.
Eight patients had histologically proven classical hippo-
campal sclerosis (HS) (Table 2). All were rendered seizure-
free after surgery. All displayed clinical features ‘‘typical’’
of MTLE + HS (Wieser, 2004) (Table S1). In all patients
except one, antiepileptic drugs (AEDs) were reduced in
number and/or daily dose during long-term follow-up. Two
patients were off AEDs; they had remained seizure-free at
last follow-up.
Another patient, with MRI-negative temporal lobe epi-
lepsy, had a right neocorticectomy and amygdalectomy,
with nonspecific findings at histopathology, and after
7 years of seizure freedom, began again to have infrequent
partial seizures. One patient with a hamartoma had a right
anterior temporal lobectomy, but was never rendered sei-
zure-free. There were no unexpected findings in other
domains during postsurgical follow-up.
Discussion
In patients with drug-resistant MTLE + HS, surgery is
more effective in stopping disabling seizures than medical
treatment alone (Wiebe et al., 2001). Recent studies also
suggest that such surgery can benefit longevity (Choi et al.,
2008) and quality of life (Zupanc et al., 2010). Around
one-third of patients who undergo surgery fail to become
seizure-free, the causes for which are uncertain; the propor-
tion not seizure-free increases at longer-term follow-up
Table 1. List of heterozygous 16p13.11microdeletions or othermicrodeletions >1 Mb inMTLE patients who had
resective surgery
Case ID Cytoband Breakpoints Size (Mb) Gene list
1 16p13.11 chr16:15387380–16225138 0.8 MPV17L, C16orf45, NDE1,MYH11, C16orf63, ABCC1, ABCC6
2 16p13.11 chr16:15387380–16225138 0.8 MPV17L, C16orf45, NDE1,MYH11, C16orf63, ABCC1, ABCC6
3 7q31.32–31.33 chr7:123252578–126117199 2.9 HYAL4, SPAM1, LOC136157, GPR37, POT1, GRM8
4 17p12 chr17:14040467–15411904 1.4 COX10, CDRT15,HS3ST3B1, PMP22, TEKT3, CDRT4, FAM18B2
5 4q32.3 chr4:167446375–168643447 1.2 SPOCK3
6 17q12 chr17:31922987–33333394 1.4 ZNHIT3,MYO19, PIGW, GGNBP2,DHRS11, MRM1, LHX1, AATF,
ACACA, C17orf78, TADA2L, DUSP14, AP1GBP1, DDX52,HNF1B,
LOC284100
7 15q11.2 chr15:18285782–20868229 1.3 OR4N4, NIPA2, NIPA1, TUBGCP5, CYFIP1, HERC2P2, A26B1 (POTEB),
OR4M2, AC131280.9, AC126603.9, AC116165.7, AC026495.13,
AC025884.28, AC138701.3, AC127381.4, AC126335.16,
AC091565.10, AC134980.3, AC138649.2
8 15q11.2 chr15:18822307–19852603 1.0 AC025884.28, AC026495.13,OR4N4, OR4M2, AC131280.9,
AC134980.3, AC126335.16, A26B1
9 4q35.2 chr4:189052964–190737252 1.97 AC093909.2, AC020698.4, TRIML2, TRIML1, ZFP42
10 16p13.11 chr16:15387380–16198600 0.8 MPV17L, C16orf45, NDE1,MYH11, C16orf63, ABCC1, ABCC6
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(Wieser, 2004). Although several predictors of outcome are
known or proposed at a group level, including presence of
HS, absence of generalized tonic–clonic seizures, larger
extent of mesiotemporal resection, and unilateral interictal
epileptiform activity (Wyler et al., 1995; Radhakrishnan
et al., 1998; Engel et al., 2003; Tonini et al., 2004; Janszky
et al., 2005; Spencer et al., 2005; Spencer & Huh, 2008),
there are no universally accepted outcome predictors for
MTLE + HS at an individual level. Such predictors would
assist in estimating risk/benefit ratio for each patient more
accurately.
Genetic factors might be postulated to contribute to out-
come, and indeed to causation of MTLE + HS. Familial
MTLE exists (Berkovic et al., 1994, 1996; Crompton et al.,
2010). Some argue that familial MTLE with HS/hippocam-
pal atrophy is clinically indistinguishable from sporadic
MTLE + HS (Kobayashi et al., 2003a; Gambardella et al.,
2009). No genetic cause of familial MTLE is known. In
addition, no genetic determinant for susceptibility to
sporadic MTLE + HS, or for predicting outcome after epi-
lepsy surgery, has been confirmed (Kanemoto et al., 2000;
Stçgmann et al., 2002; Cavalleri et al., 2005, 2007;
Kasperaviciute et al., 2010).
Microdeletions are becoming recognized as an important
potential genetic cause of, or predisposition to, a wide range
of epilepsies. Although some microdeletions may be chance
findings, large microdeletions are likely to be associated
with disease (Scheffer & Berkovic, 2010), and we showed
changes in gene expression with 16p13.11 microdeletions,
and noted that many known epilepsy genes, for example,
KCNA1, GABRA1, and GABRG2, can be involved in
microdeletions (Heinzen et al., 2010). It is important to note
that many of these microdeletions seem to act as risk factors
rather than as the sole underlying cause, and that some
microdeletions are found in people without epilepsy or a
family history of epilepsy, although at much reduced fre-
quency (Sisodiya &Mefford, 2011). Although more work is
required to characterize microdeletions and their pathogenic
mechanisms, significant microdeletions are likely to be
found in many other patients, including those being consid-
ered for epilepsy surgery. Because these microdeletions
might affect outcome after surgical treatment, it is important
to systematically evaluate their influence.
The seizure-free rate in our patients with putatively path-
ogenic microdeletions seems as good as reported for cohorts
in the literature (McIntosh et al., 2001; Spencer & Huh,
2008; Dunlea et al., 2010). Although this observation must
be tempered by the small size of our microdeletion cohort
and requires further confirmation, we show that having a
large microdeletion does not preclude seizure-free outcome
after surgery for MTLE. Although our findings may relate
to specific microdeletions, our seizure-free patients had
seven different microdeletions, and had a good postsurgical
outcome in other domains as well, not just seizure control
(Table S1). The psychiatric outcome varied, with presurgi-
cal psychiatric comorbidity common in the cases with post-
surgical psychiatric issues, as reported previously in the
literature (Kanner et al., 2009).
There are other examples in the literature of epilepsies
with a genetic basis and a good outcome after resective
Table 2. Main findings of neuropathology analysis of temporal lobectomy specimen
Case ID Main pathologic findings in temporal neocortex Main pathologic findings in hippocampus Summary of main pathologic findings
1 Small glioneuronal hamartoma in middle
temporal gyrus white matter
Only CA1 available for analysis;
neuronal loss not seen
No hippocampal sclerosis but
specimen incomplete. Hamartoma
2 Focal neuronal loss and gliosis in superficial
cortex in pole (TLS) (Thom et al., 2009)
Neuronal loss and gliosis particularly
in CA1 and CA4. Mild GCD
Classical hippocampal sclerosis
3 Cortex normal Neuronal loss and gliosis particularly
in CA1 and CA4. Moderate GCD
Classical hippocampal sclerosis
4 Gliosis only. No dysplasia Incomplete representation of subfields.
CA1 neuronal loss and gliosis. GCD
Classical hippocampal sclerosis
5 Patchy cortical and white matter gliosis Neuronal loss and gliosis particularly
in CA1 and CA4. Moderate GCD
Classical hippocampal sclerosis
6 Cortex normal Neuronal loss in CA4 and CA1 and
gliosis
Classical hippocampal Sclerosis
7 Numerous corpora amylacea in white matter Incomplete representation of subfields.
CA1 and CA4 neuronal loss and gliosis.
Mild GCD and some depletion of GC
Classical hippocampal sclerosis
8 N/Aa Neuronal loss and gliosis particularly in
CA1 and CA4
Classical hippocampal sclerosis.
9 N/Aa Moderate to marked astrogliosis Classical hippocampal sclerosis
10 Patchy laminar reactive astrogliosis Amygdala included, but hippocampal
structures not present in specimenb
Nonspecific findings
aThese patients had selective amygdalohippocampectomy.
bThis patient had neocorticectomy and amygdalectomy.
GC(D), Granule cell (dispersion); N/A, not applicable; TLS, temporal lobe sclerosis (Thom et al., 2009).
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surgery for drug-resistant seizures. In families with
SCN1B-positive genetic epilepsy with febrile seizures plus
(GEFS+), an excellent outcome has been reported after
anterior temporal lobectomy for affected individuals with
drug-resistant MTLE + HS (Scheffer et al., 2007). A small
series of patients with tuberous sclerosis complex, with con-
firmed mutations in the TSC1 (n = 2) and TSC2 (n = 2)
genes, had discrete epileptogenic brain lesions that were
resected, and were seizure-free on AEDs at last follow-up
after surgery (Hirfanoglu & Gupta, 2010). Postsurgical sei-
zure outcome in patients with familial MTLE with
HS/hippocampal atrophy, for which no known genetic cause
is actually yet known, does not differ from that in sporadic
MTLE with HS/hippocampal atrophy (Kobayashi et al.,
2003b).
Our findings suggest that large microdeletions do not nec-
essarily preclude a good prognosis following epilepsy sur-
gery, if surgery is a reasonable option based on concordance
of other data during presurgical evaluation. Further studies
will be important to firmly establish the mechanisms of
MTLE associated with large microdeletions. As more puta-
tively causal genetic variants of all classes are uncovered, it
will also become important to address their impact on clini-
cal management.
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